Cargando…

The Quest for a Respiratory Syncytial Virus Vaccine for Older Adults: Thinking beyond the F Protein

Respiratory syncytial virus (RSV) is a common cause of paediatric respiratory tract infection and causes a significant health burden in older adults. Natural immunity to RSV is incomplete, permitting recurrent symptomatic infection over an individual’s lifespan. When combined with immunosenescence,...

Descripción completa

Detalles Bibliográficos
Autores principales: Jenkins, Victoria A., Hoet, Bernard, Hochrein, Hubertus, De Moerlooze, Laurence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9963583/
https://www.ncbi.nlm.nih.gov/pubmed/36851260
http://dx.doi.org/10.3390/vaccines11020382
_version_ 1784896287484674048
author Jenkins, Victoria A.
Hoet, Bernard
Hochrein, Hubertus
De Moerlooze, Laurence
author_facet Jenkins, Victoria A.
Hoet, Bernard
Hochrein, Hubertus
De Moerlooze, Laurence
author_sort Jenkins, Victoria A.
collection PubMed
description Respiratory syncytial virus (RSV) is a common cause of paediatric respiratory tract infection and causes a significant health burden in older adults. Natural immunity to RSV is incomplete, permitting recurrent symptomatic infection over an individual’s lifespan. When combined with immunosenescence, this increases older adults’ susceptibility to more severe disease symptoms. As RSV prophylaxis is currently limited to infants, older adults represent an important target population for RSV vaccine development. The relationship between RSV and our immune systems is complex, and these interactions require deeper understanding to tailor an effective vaccine candidate towards older adults. To date, vaccine candidates targeting RSV antigens, including pre-F, F, G (A), G (B), M2-1, and N, have shown efficacy against RSV infection in older adults in clinical trial settings. Although vaccine candidates have demonstrated robust neutralising IgG and cellular responses, it is important that research continues to investigate the RSV immune response in order to further understand how the choice of antigenic target site may impact vaccine effectiveness. In this article, we discuss the Phase 3 vaccine candidates being tested in older adults and review the hurdles that must be overcome to achieve effective protection against RSV.
format Online
Article
Text
id pubmed-9963583
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99635832023-02-26 The Quest for a Respiratory Syncytial Virus Vaccine for Older Adults: Thinking beyond the F Protein Jenkins, Victoria A. Hoet, Bernard Hochrein, Hubertus De Moerlooze, Laurence Vaccines (Basel) Review Respiratory syncytial virus (RSV) is a common cause of paediatric respiratory tract infection and causes a significant health burden in older adults. Natural immunity to RSV is incomplete, permitting recurrent symptomatic infection over an individual’s lifespan. When combined with immunosenescence, this increases older adults’ susceptibility to more severe disease symptoms. As RSV prophylaxis is currently limited to infants, older adults represent an important target population for RSV vaccine development. The relationship between RSV and our immune systems is complex, and these interactions require deeper understanding to tailor an effective vaccine candidate towards older adults. To date, vaccine candidates targeting RSV antigens, including pre-F, F, G (A), G (B), M2-1, and N, have shown efficacy against RSV infection in older adults in clinical trial settings. Although vaccine candidates have demonstrated robust neutralising IgG and cellular responses, it is important that research continues to investigate the RSV immune response in order to further understand how the choice of antigenic target site may impact vaccine effectiveness. In this article, we discuss the Phase 3 vaccine candidates being tested in older adults and review the hurdles that must be overcome to achieve effective protection against RSV. MDPI 2023-02-07 /pmc/articles/PMC9963583/ /pubmed/36851260 http://dx.doi.org/10.3390/vaccines11020382 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Jenkins, Victoria A.
Hoet, Bernard
Hochrein, Hubertus
De Moerlooze, Laurence
The Quest for a Respiratory Syncytial Virus Vaccine for Older Adults: Thinking beyond the F Protein
title The Quest for a Respiratory Syncytial Virus Vaccine for Older Adults: Thinking beyond the F Protein
title_full The Quest for a Respiratory Syncytial Virus Vaccine for Older Adults: Thinking beyond the F Protein
title_fullStr The Quest for a Respiratory Syncytial Virus Vaccine for Older Adults: Thinking beyond the F Protein
title_full_unstemmed The Quest for a Respiratory Syncytial Virus Vaccine for Older Adults: Thinking beyond the F Protein
title_short The Quest for a Respiratory Syncytial Virus Vaccine for Older Adults: Thinking beyond the F Protein
title_sort quest for a respiratory syncytial virus vaccine for older adults: thinking beyond the f protein
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9963583/
https://www.ncbi.nlm.nih.gov/pubmed/36851260
http://dx.doi.org/10.3390/vaccines11020382
work_keys_str_mv AT jenkinsvictoriaa thequestforarespiratorysyncytialvirusvaccineforolderadultsthinkingbeyondthefprotein
AT hoetbernard thequestforarespiratorysyncytialvirusvaccineforolderadultsthinkingbeyondthefprotein
AT hochreinhubertus thequestforarespiratorysyncytialvirusvaccineforolderadultsthinkingbeyondthefprotein
AT demoerloozelaurence thequestforarespiratorysyncytialvirusvaccineforolderadultsthinkingbeyondthefprotein
AT jenkinsvictoriaa questforarespiratorysyncytialvirusvaccineforolderadultsthinkingbeyondthefprotein
AT hoetbernard questforarespiratorysyncytialvirusvaccineforolderadultsthinkingbeyondthefprotein
AT hochreinhubertus questforarespiratorysyncytialvirusvaccineforolderadultsthinkingbeyondthefprotein
AT demoerloozelaurence questforarespiratorysyncytialvirusvaccineforolderadultsthinkingbeyondthefprotein